Search Within

Connie Wing-Ching Lee Batlevi

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (50)
  2. Journal Article (33)
  3. Research Letter (4)
  4. Book Section (1)
  5. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (89)
  2. Department of Medicine (89)
  3. Epidemiology and Biostatistics (89)
  4. Hematologic Malignancies, Division of (89)
  5. Lymphoma (89)
  6. Survivorship Research (76)

More Groups

People
  1. Maria Palomba (65)
  2. Andrew Zelenetz (51)
  3. Anas Younes (49)
  4. Matthew Matasar (48)
  5. Paul Hamlin (42)
  6. Anita Kumar (41)

More People

Years
  1. 2024 (1)
  2. 2023 (9)
  3. 2022 (15)
  4. 2021 (12)
  5. 2020 (17)
  6. 2019 (16)

More Years

Publications
  1. Blood (33)
  2. Blood Advances (12)
  3. Hematological Oncology (8)
  4. Blood Cancer Journal (6)
  5. Journal of Clinical Oncology (5)
  6. Transplantation and Cellular Therapy (4)

More Publications

Publishers
  1. American Society of Hematology (45)
  2. Nature Publishing Group (11)
  3. Elsevier Inc. (10)
  4. Wiley Blackwell (8)
  5. American Society of Clinical Oncology (5)
  6. Taylor & Francis Group (3)

More Publishers

Results (89)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
    Journal Article

    Bobillo, S.; Joffe, E.; Sermer, D.; Mondello, P.; Ghione, P.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; more...
    Blood Cancer Journal (2021)

    Fulltext@MSK | Save
  • The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy
    Journal Article

    Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Shouval, R.; Afuye, A. O.; Silverberg, M. L.; Batlevi, C. W.; Dahi, P.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
    Journal Article

    Joffe, E.; Leyfman, Y.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Lia Palomba, M.; Moskowitz, C. H.; Portlock, C.; Noy, A.; Horwitz, S. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
    Research Letter

    Lin, R. J.; Lobaugh, S. M.; Pennisi, M.; Chan, H. T.; Batlevi, Y.; Ruiz, J. D.; Elko, T. A.; Maloy, M. A.; Batlevi, C. L.; Dahi, P. B.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas
    Meeting Abstract

    Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
    Blood (2020)

    Fulltext@MSK | Save